Patents by Inventor Rachel Soloff Nugent

Rachel Soloff Nugent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180319889
    Abstract: The present invention relates to a method and a medicament for airway and/or lung diseases such as moderate and/or severe asthma disease, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and systemic sclerosis. The medicament contains an agent which inhibits TL1A-DR3 interaction, and the method involves administering an effective amount of the agent to a subject to inhibit at least one symptom, feature or condition selected from hyperplasia of epithelial cells, epithelial metaplasia, hypertrophy of smooth muscle cells, and hyperproliferation of smooth muscle cells, production of extracellular matrix, and/or airway and/or lung tissue remodeling.
    Type: Application
    Filed: November 2, 2016
    Publication date: November 8, 2018
    Applicants: La Jolla Institute for Allergy & Immunology, KYOWA HAKKO KIRIN CO., LTD
    Inventors: Michael CROFT, Rana HERRO, David MILLS, Rachel SOLOFF NUGENT, Monica LEUNG
  • Publication number: 20180298107
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Application
    Filed: May 14, 2018
    Publication date: October 18, 2018
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Patent number: 9969810
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: May 15, 2018
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Publication number: 20170081417
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 23, 2017
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichiro KATO, Rachel SOLOFF NUGENT, Hitoshi YOSHIDA, Michael CROFT
  • Patent number: 9475878
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: October 25, 2016
    Assignees: KYOWA HAKKO KIRIN CO., LTD, LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Publication number: 20140044703
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Application
    Filed: August 31, 2012
    Publication date: February 13, 2014
    Applicants: La Jolla Institute For Allergy And Immunology, Kyowa Hakko Kirin Co., Ltd.
    Inventors: SHINICHIRO KATO, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Patent number: 8420784
    Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: April 16, 2013
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Tomoyuki Tahara, Paul Rogers, Aihua Song
  • Patent number: 8283450
    Abstract: The invention provides antibodies that specifically bind to OX40 (CD134), referred to as OX40 antibodies, anti-OX40 or anti-OX40 antibodies. Invention antibodies that specifically bind to OX40 include mammalian (human, primate, etc.), humanized and chimeric anti-OX40 antibodies. Invention antibodies and antibody subsequences (fragments) that specifically bind to OX40 include purified and isolated antibodies, as well as pharmaceutical formulations thereof, are useful in various methods including treatment, screening and detection methods.
    Type: Grant
    Filed: November 27, 2006
    Date of Patent: October 9, 2012
    Assignees: Kyowa Hakko Kirin Co., Ltd., La Jolla Institute for Allergy and Immunology
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Hitoshi Yoshida, Michael Croft
  • Publication number: 20110144312
    Abstract: The invention relates to IL-1O Receptor alpha (IL-1OR?) antibodies and subsequences thereof, human and humanized IL-10 Receptor alpha (IL-IOR?) antibodies and subsequences thereof, isolated and purified IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, compositions including IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof, and methods that employ IL-10 Receptor alpha (IL-1OR?) antibodies and subsequences thereof. The invention includes among other things, methods of treating a pathogen infection, pathogen reactivation, and methods of vaccinating or immunizing against a pathogen infection, which include, for example, administering an IL-10 Receptor alpha (IL-1OR?) antibody or subsequence, to treat a pathogen infection, pathogen reactivation or for vaccination or immunization.
    Type: Application
    Filed: May 27, 2009
    Publication date: June 16, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichiro Kato, Rachel Soloff Nugent, Tomoyuki Tahara, Paul Rogers, Aihua Song